Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

16 Jun 2011
ProImmune introduces new uniquely powerful protein and peptide array platform

ProImmune introduces new uniquely powerful protein and peptide array platform

16 Jun 2011
Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

13 Jun 2011
Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

13 Jun 2011
PharmAthene to sell $6.5M of common stock and warrants in registered direct offering

PharmAthene to sell $6.5M of common stock and warrants in registered direct offering

10 Jun 2011
Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

10 Jun 2011
Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

9 Jun 2011
Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

9 Jun 2011
Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

8 Jun 2011
Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

8 Jun 2011
Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

7 Jun 2011
VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

7 Jun 2011
Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

7 Jun 2011
Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

6 Jun 2011
TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

6 Jun 2011
Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

6 Jun 2011
Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

4 Jun 2011
Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

4 Jun 2011
Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

4 Jun 2011
IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

3 Jun 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback